Vol 11, No 1 (2010): Practical Diabetology
Research paper
Published online: 2010-04-21
Cost-utility analysis for insulin aspart and biphasic insulin aspart in treatment of type 1 and 2 diabetes mellitus
Diabetologia Praktyczna 2010;11(1):24-34.
Abstract
INTRODUCTION. In this analysis costs and utilities of
treatment with rapid-acting and biphasic insulin
analogues (aspart) were compared with those of
human insulin in patients with type 1 and 2 diabetes
mellitus.
MATERIAL AND METHODS. This cost-utility analysis was based on the CORE Diabetes Model, adapted to Polish circumstances. Two comparisons were performed: insulin aspart vs. human insulin in a multiple injection regimen in type 1 diabetes mellitus and biphasic insulin aspart vs. human insulin mixture in type 2 diabetes mellitus. The enhanced payer’s perspective was adopted, i.e. total costs incurred by the public payer and the patient were taken into account. Health effects were expressed in quality-adjusted life years (QALY).
RESULTS. Type 1 diabetes mellitus. The mean number of QALY gained was 5.39 in the aspart group and 4.85 in the human insulin group. Costs of treatment per patient were 53,454 PLN for treatment with insulin aspart and 50,048 PLN for treatment with human insulin. The cost for an additional QALY gained was 6,351 PLN. Type 2 diabetes mellitus. The mean number of QALY was 5.06 for biphasic insulin aspart and 4.95 for human insulin mixture. Costs of treatment per patient were 30,079 PLN for treatment with biphasic insulin aspart and those generated by human insulin mixture were 24,970 PLN. The cost for an additional QALY gained was 49,425 PLN.
CONCLUSIONS. Both rapid-acting and biphasic insulin aspart improve quality of life of patients with type 1 and 2 diabetes mellitus in comparison with human insulin. In Polish circumstances they are cost-effective treatment options. This was confirmed by a high cost-utility ratio, which in both cases was lower than the cost-utility threshold assumed in Poland.
(Diabet. Prakt. 2010; 11, 1: 24-34)
MATERIAL AND METHODS. This cost-utility analysis was based on the CORE Diabetes Model, adapted to Polish circumstances. Two comparisons were performed: insulin aspart vs. human insulin in a multiple injection regimen in type 1 diabetes mellitus and biphasic insulin aspart vs. human insulin mixture in type 2 diabetes mellitus. The enhanced payer’s perspective was adopted, i.e. total costs incurred by the public payer and the patient were taken into account. Health effects were expressed in quality-adjusted life years (QALY).
RESULTS. Type 1 diabetes mellitus. The mean number of QALY gained was 5.39 in the aspart group and 4.85 in the human insulin group. Costs of treatment per patient were 53,454 PLN for treatment with insulin aspart and 50,048 PLN for treatment with human insulin. The cost for an additional QALY gained was 6,351 PLN. Type 2 diabetes mellitus. The mean number of QALY was 5.06 for biphasic insulin aspart and 4.95 for human insulin mixture. Costs of treatment per patient were 30,079 PLN for treatment with biphasic insulin aspart and those generated by human insulin mixture were 24,970 PLN. The cost for an additional QALY gained was 49,425 PLN.
CONCLUSIONS. Both rapid-acting and biphasic insulin aspart improve quality of life of patients with type 1 and 2 diabetes mellitus in comparison with human insulin. In Polish circumstances they are cost-effective treatment options. This was confirmed by a high cost-utility ratio, which in both cases was lower than the cost-utility threshold assumed in Poland.
(Diabet. Prakt. 2010; 11, 1: 24-34)
Keywords: diabetesaspartQALYcost